公开(公告)号：US09624309B2

公开(公告)日：2017-04-18

申请号：US12671942

申请日：2008-08-16

申请人： Bing Liu ,  David Light ,  Zhuozhi Wang ,  Douglas Schneider

发明人： Bing Liu ,  David Light ,  Zhuozhi Wang ,  Douglas Schneider

IPC分类号： A61K39/395 ,  C07K16/46 ,  A61K47/48 ,  C07K16/30 ,  C07K16/36 ,  A61K39/00

CPC分类号： C07K16/468 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6821 ,  A61K47/6827 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/3069 ,  C07K16/3076 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/64 ,  Y02A50/412

摘要： This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.

公开(公告)号：US20090269350A1

公开(公告)日：2009-10-29

申请号：US12316681

申请日：2008-12-16

申请人： Maria A. Glucksmann ,  Mark J. Williamson ,  Fong-Ying Tsai ,  Laura A. Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel E. Meyers ,  Lillian Wei-Ming Chiang ,  John Joseph Hunter

发明人： Maria A. Glucksmann ,  Mark J. Williamson ,  Fong-Ying Tsai ,  Laura A. Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel E. Meyers ,  Lillian Wei-Ming Chiang ,  John Joseph Hunter

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12N5/00 ,  C07K14/00 ,  C07K16/00 ,  C12P21/06 ,  C12Q1/68 ,  G01N33/53 ,  A61K31/7088 ,  A61K38/16

CPC分类号： C12N9/1288 ,  A01K2217/05 ,  A61K38/00 ,  A61K47/6805 ,  A61K47/6809 ,  A61K47/6821 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4747 ,  C07K2319/00 ,  C12N9/14 ,  C12N9/16 ,  C12N9/6472 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2500/10

摘要： The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子和蛋白质，命名为27411,23413,22438,23553,25278,26212，NARC SC1，NARC 20A，NARC 1，NARC 12，NARC 13，NARC 17，NARC 25，NARC 3，NARC 4，NARC 7，NARC 8，NARC 11，NARC 14A，NARC 15，NARC 16，NARC 19，NARC 20，NARC 26，NARC 27，NARC 28，NARC 30，NARC 5，NARC 6，NARC 9，NARC 10C，NARC 8B， NARC 9，NARC2A，NARC 16B，NARC 1C，NARC 1A，NARC 25，86604和32222核酸分子和蛋白质。 本发明还提供了反义核酸分子，含有所述核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，其中所述基因已导入或破坏的非人类转基因动物，融合蛋白，抗原肽和抗体 到蛋白质。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US20030113777A1

公开(公告)日：2003-06-19

申请号：US10284059

申请日：2002-10-30

申请人： Millennium Pharmaceuticals, Inc.

发明人： John Joseph Hunter

IPC分类号： A61K048/00 ,  A61K038/17 ,  A61K031/00 ,  C12Q001/68 ,  G01N033/567 ,  A61K039/395

CPC分类号： G01N33/57484 ,  A61K38/00 ,  A61K47/6805 ,  A61K47/6809 ,  A61K47/6821 ,  A61K2039/505 ,  C07K2319/00 ,  C12N9/14 ,  G01N33/5011

摘要： The present invention relates to methods and compositions for the treatment and diagnosis of cellular proliferative disorders, including, but not limited to, lung, breast, ovary, and colon tumors. The invention further provides methods for identifying a compound capable of treating a cellular proliferative disorder or modulating tumorigenesis. The invention also provides a method for modulating tumorigenesis, e.g., modulating tumorigenesis in a subject. In addition, the invention provides a method for treating a subject having a cellular proliferative disorder characterized by aberrant 32222 polypeptide activity or aberrant 32222 nucleic acid expression.

摘要翻译： 本发明涉及用于治疗和诊断细胞增殖性疾病的方法和组合物，包括但不限于肺，乳腺，卵巢和结肠肿瘤。 本发明还提供了鉴定能够治疗细胞增殖性疾病或调节肿瘤发生的化合物的方法。 本发明还提供了调节肿瘤发生的方法，例如调节受试者的肿瘤发生。 此外，本发明提供了治疗具有以异常32222多肽活性或异常32222核酸表达为特征的细胞增殖性疾病的受试者的方法。

公开(公告)号：US20240117022A1

公开(公告)日：2024-04-11

申请号：US18352430

申请日：2023-07-14

申请人： Astellas Pharma Inc. ,  Tron - Translationale onkologie an der universitätsmedizin der Johannes Gutenb

发明人： Ugur Sahin ,  Özlem Türeci ,  Dirk Usener ,  Stefan Fritz ,  Christoph Uherek ,  Gunda Brandenburg ,  Harald-Gerhard Geppert ,  Anja Kristina Schröder ,  Phillippe Thiel

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K51/1063 ,  C07K16/28 ,  C07K16/3046 ,  A61K2039/505 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734

摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

公开(公告)号：US09751934B2

公开(公告)日：2017-09-05

申请号：US14661882

申请日：2015-03-18

申请人： Ganymed Pharmaceuticals AG

发明人： Ugur Sahin ,  Özlem Türeci ,  Dirk Usener ,  Stefan Fritz ,  Christoph Uherek ,  Gunda Brandenburg ,  Harald-Gerhard Geppert ,  Anja Kristina Schröder ,  Phillippe Thiel

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/18 ,  A61K47/48 ,  A61K51/10 ,  C07K16/30 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K51/1063 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

公开(公告)号：US20150252103A1

公开(公告)日：2015-09-10

申请号：US14661846

申请日：2015-03-18

申请人： Ganymed Pharmaceuticals AG

发明人： Ugur Sahin ,  Özlem Türeci ,  Dirk Usener ,  Stefan Fritz ,  Christoph Uherek ,  Gunda Brandenburg ,  Harald-Gerhard Geppert ,  Anja Kristina Schröder ,  Phillippe Thiel

IPC分类号： C07K16/18 ,  A61K45/06 ,  A61K39/395

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K51/1063 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

公开(公告)号：US20110229476A1

公开(公告)日：2011-09-22

申请号：US12671942

申请日：2008-08-16

申请人： Bing Liu ,  David Light ,  Zhuozhi Wang ,  Douglas Schneider

发明人： Bing Liu ,  David Light ,  Zhuozhi Wang ,  Douglas Schneider

IPC分类号： A61K39/395 ,  C07K16/44 ,  G01N33/53 ,  C12N9/96 ,  A61P35/00 ,  A61P35/02 ,  A61P29/00 ,  A61P3/10 ,  A61P25/00 ,  A61P19/02 ,  A61P7/06 ,  A61P17/06 ,  A61P1/12 ,  A61P33/06 ,  A61P31/04 ,  A61P31/00 ,  A61P31/18 ,  A61P31/06 ,  A61P31/14 ,  A61P31/20

CPC分类号： C07K16/468 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6821 ,  A61K47/6827 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/3069 ,  C07K16/3076 ,  C07K16/36 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/64 ,  Y02A50/412

摘要： This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.

摘要翻译： 本发明涉及可用于诊断和治疗各种疾病的单特异性和多特异性抗体。 此外，这些抗体可以通过蛋白酶切割来修饰。 蛋白酶控制或调节可以由位于例如接头的蛋白酶位点提供。 这些蛋白酶调节的抗体也可用于各种疾病的诊断和治疗。

公开(公告)号：US20060159683A1

公开(公告)日：2006-07-20

申请号：US11024877

申请日：2004-12-30

申请人： Andreas Pluckthun ,  Annemarie Honegger ,  Jorg Willuda

发明人： Andreas Pluckthun ,  Annemarie Honegger ,  Jorg Willuda

IPC分类号： A61K39/395 ,  C07K16/30 ,  G01N33/574

CPC分类号： C07K16/00 ,  A61K47/6813 ,  A61K47/6819 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6825 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6877 ,  A61K51/1045 ,  A61K51/1087 ,  A61K2039/505 ,  C07K16/06 ,  C07K16/28 ,  C07K16/30 ,  C07K16/465 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

摘要： The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.

公开(公告)号：US20060116508A1

公开(公告)日：2006-06-01

申请号：US11313836

申请日：2005-12-21

申请人： Maria Glucksmann ,  Mark Williamson ,  Fong-Ying Tsai ,  Laura Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel Meyers ,  Lillian Chiang ,  John Hunter

发明人： Maria Glucksmann ,  Mark Williamson ,  Fong-Ying Tsai ,  Laura Rudolph-Owen ,  Rosanna Kapeller-Libermann ,  Rachel Meyers ,  Lillian Chiang ,  John Hunter

IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N9/16

CPC分类号： C12N9/1288 ,  A01K2217/05 ,  A61K38/00 ,  A61K47/6805 ,  A61K47/6809 ,  A61K47/6821 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4747 ,  C07K2319/00 ,  C12N9/14 ,  C12N9/16 ,  C12N9/6472 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2500/10

摘要： The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

摘要翻译： 本发明提供分离的核酸分子和蛋白质，命名为27411,23413,22438,23553,25278,26212，NARC SC1，NARC 10A，NARC 1，NARC 12，NARC 13，NARC 17，NARC 25，NARC 3，NARC 4，NARC 7，NARC 8，NARC 11，NARC 14A，NARC 15，NARC 16，NARC 19，NARC 20，NARC 26，NARC 27，NARC 28，NARC 30，NARC 5，NARC 6，NARC 9，NARC 10C，NARC 8B， NARC 9，NARC2A，NARC 16B，NARC 1C，NARC 1A，NARC 25，86604和32222核酸分子和蛋白质。 本发明还提供了反义核酸分子，含有所述核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，其中所述基因已导入或破坏的非人类转基因动物，融合蛋白，抗原肽和抗体 到蛋白质。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：US11739139B2

公开(公告)日：2023-08-29

申请号：US16919969

申请日：2020-07-02

申请人： Astellas Pharma Inc. ,  TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENB

发明人： Ugur Sahin ,  Özlem Türeci ,  Dirk Usener ,  Stefan Fritz ,  Christoph Uherek ,  Gunda Brandenburg ,  Harald-Gerhard Geppert ,  Anja Kristina Schröder ,  Phillippe Thiel

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/18 ,  A61K47/68 ,  A61K51/10 ,  C07K16/30 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6807 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6821 ,  A61K47/6823 ,  A61K47/6829 ,  A61K47/6851 ,  A61K47/6859 ,  A61K47/6863 ,  A61K47/6869 ,  A61K51/1063 ,  C07K16/28 ,  C07K16/3046 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

摘要： The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.